|
|
马骏院士团队被接收一篇JAMA、一篇Cancer Cell，另有8项临床试验在进行中4 E2 W' E# e+ w% Y1 |' E0 K
Whole-course Concurrent and Adjuvant Nivolumab Combined with Induction Chemotherapy Followed by Radiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma (NCT03984357, Cancer Cell, 2025,已接收)3 F% u( K1 h c: D7 b6 s5 n
2 @/ N( u C- |* n
Adjuvant PD-1 Antibody in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma: a Multi-center, Randomised Controlled, Phase 3 Trial (NCT03427827, JAMA, 2025,已接收)
: k. V$ M0 V# B8 R# C. e8 j9 I7 M
8 j& t# G0 z- QGP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma (NCT06455410, 进行中)
' G' g( h G, [Individualized Elective Neck Irradiation in NPC Patients (NCT06241612, 进行中)6 X9 D( ^+ A3 s( X6 o( _
Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response (NCT06239727, 进行中)
% y* A" {( g% e: [+ q6 q) UCadonilimab (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma (NCT05587374, 进行中)
8 k8 J$ s+ z- b1 sTQB2618 Injection Combined With Penpulimab Injection in the Treatment of Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma (NCT05563480, completed)" ]: w/ c6 M W; b3 W; \$ x, ?! F
Combining MRI and CEUS to Diagnose Small Cervical Lymph Node Metastases in NPC Patients (NPC-LN) (NCT05389306, 进行中)
M1 E2 U6 c1 YMetronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma (NCT05342792, 进行中)
3 s0 _0 p+ s G$ ~Single-agent Capecitabine as Metronomic Chemotherapy in LAHNSCC (CMHN) (NCT05044117, 进行中) |
|
发表于 
楼主
